White Paper

Mitigating Trial Risk In ALS Clinical Development

Source: IQVIA Research & Development Solutions
PatientsLikeMe And Duke Bring Novel Approach To ALS Trial

Although relatively rare (5/100,000 in the USA), Amyotrophic Lateral Sclerosis (ALS) is a devastating, progressive and ultimately fatal neurodegenerative disease that profoundly impacts patients and their families. 

The development of new treatments has been slow, with only two approved disease-modifying drugs that offer limited benefit. But significant advances in immuno-neurology have set the stage for promising novel treatments that could offer hope to these families and change the course of this disease.

The lack of available treatments for ALS has led many ALS patients to view clinical research as the best available care option. That can make it easier for sponsors to attract patients to their trials.

Though, while they may be generally eager to participate, researchers still have take the time to understand the unique needs of these patients and their families so they can make participation feasible and strengthen engagement. That requires thoughtful upfront planning, and a clear understanding of the obstacles patients face when participating in an ALS trial.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader